Prospective Study of Chikungunya Virus Acute Infection in the Island of La Réunion during the 2005–2006 Outbreak

Institut Pasteur, France
PLoS ONE (Impact Factor: 3.53). 10/2009; 4(10):e7603. DOI: 10.1371/journal.pone.0007603
Source: PubMed

ABSTRACT Chikungunya virus (CHIKV) is a recently re-emerged arthropod borne virus responsible for a massive outbreak in the Indian Ocean and India, and extended to Southeast Asia as well as Italy. CHIKV has adapted to Aedes albopictus, an anthropophilic mosquito species widely distributed in Asia, Europe, Africa and America. Our objective was to determine the clinical and biological features of patients at the acute phase of CHIKV infection.
A prospective study enrolled 274 consecutive patients with febrile arthralgia recorded at the Emergency Department of the Groupe Hospitalier Sud-Réunion between March and May 2006. Three groups were defined: one group of 180 viremic patients (positive CHIKV RT-PCR), one group of 34 patients with acute post-viremic infection (negative CHIKV RT-PCR, positive anti-CHIKV IgM and negative IgG), and one group of 46 uninfected patients (negative CHIKV RT-PCR, anti-CHIKV IgM and IgG). Bivariate analyses of clinical and biological features between groups were performed. Patients with CHIKV viremia presented typically with asymmetrical bilateral polyarthralgia (96.5%) affecting the lower (98%) and small joints (74.8%), as well as asthenia (88.6%), headache (70%), digestive trouble (63.3%), myalgia (59%), exanthems (47.8%), conjunctival hyperhemia (23%) and adenopathy (8.9%). Vertigo, cutaneous dysesthesia, pharyngitis and haemorrhages were seldom observed. So far unreported symptoms such as chondrocostal arthralgia (20%), entesopathies (1.6%), talalgia (14%) were also noted. Prurit was less frequent during the viremic than post-viremic phase (13.9% vs. 41.2%; p<0.001), whereas lymphopenia was more frequent (87.6% vs. 39.4%; p<0.001). Others biological abnormalities included leukopenia (38.3%), thrombocytopenia (37.3%), increased ASAT and ALAT blood levels (31.6 and 7.3%, respectively) and hypocalcemia (38.7%). Lymphopenia <1,000/mm(3) was very closely associated with viremic patients (Yule coefficient 0.82, positive predictive value 92.3%). Age under 65 was associated with a benign course, as no patients younger than 65 had to be hospitalized (Yule coefficient 0.78).
The diagnosis of CHIKV infection in acute phase is based on commonly accepted clinical criteria (fever and arthralgia), however clinical and biological diffrences exist in acute phase depending on whether or not the patient is within the viremic phase of the infection.


Available from: Marc Lecuit, Jun 03, 2015
  • New England Journal of Medicine 03/2015; 372(13):1231-9. DOI:10.1056/NEJMra1406035 · 54.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: for Colombia the arrival of the Chikungunya virus (CHIKV) constitutes a potential problem of public health due to in the country as much in rural as urban areas, the presence of the A. Aegypti mosquito, vector of the infection, the same of the dengue virus, is endemic. Objective: To carry out a thematic review referent to the CHIKV and to the febrile syndrome that it causes. Methods: Descriptive bibliographic review, with search in the databases: PubMed, Scopus, ScienceDirect, OvidSP and Medline; including review articles, case reports and clinical trials. Results: 107 articles were found, from which 78 documents were used for convenience between review, research reports, case reports, bulletins and epidemiological reports. Conclusions: The CHIKV is an Alphavirus with an only serotype described. It is one of the 29 species belong to the Alphavirus genus of the Togaviridae family and has two cycles of transmission: Sylvatic or enzootic and urban or epizootic. The incubation period varies between one and twelve days. High fever, cutaneous rash and severe osteoarticular pain are the clinical characteristics that appear in six days, with low lethality and that are difficult to differenciate of other tropical diseases, including Malaria and Dengue. In the majority of the cases, a permanent immunity is acquired. The treatment of the disease is symptomatic and available vaccine does not exist. The sanity authorities must strengthen the programs of vector control to confront this tropical disease. Rev.cienc.biomed. 2014;5(2):317-328. KEYWORDS Chikungunya virus; Chikungunya virus infection; Alphavirus; Alphavirus infections
  • [Show abstract] [Hide abstract]
    ABSTRACT: Since first reported in the Americas in December 2013, chikungunya virus (CHIKV) infections have been documented in travelers returning from the Caribbean, with many cases identified by CHIKV antibody and/or RNA testing at our laboratory. We used our large dataset to characterize the relationship between antibody titers and RNA detection, and to estimate IgM persistence. CHIKV RNA was measured by nucleic acid amplification, CHIKV IgG/IgM by indirect immunofluorescence. Of 1306 samples submitted for RNA testing January-September 2014, 393 (30%) were positive; 166 RNA-positive samples also had CHIKV antibody testing ordered, and 84% were antibody-negative. Of 6971 sera submitted for antibody testing January-September 2014, 1811 (26%) were IgM-positive; 1461 IgM-positives (81%) were IgG-positive. The relationship between CHIKV antibody titers and RNA detection was evaluated using 376 IgM-positive samples (138 with RNA testing ordered, 238 de-identified and tested for RNA). RNA detection showed no significant association with IgM titer, but was inversely related to IgG titer; 63% of IgG-negative sera were RNA-positive, compared to 36% of sera with low IgG titers (1:10-1:80) and 16% with IgG titers ≥1:160. Using second-sample results from 62 seroconverters, we estimated that CHIKV IgM persists for 110 days (95% confidence interval 78-150 days) after the initial antibody-negative sample. These findings indicate that (a) RNA detection is more sensitive than antibody detection early in CHIKV infection; (b) in the absence of RNA results, the IgG titer of IgM-positive samples may be a useful surrogate for viremia; and (c) CHIKV IgM persists for approximately 4 months after symptom onset. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
    Clinical and vaccine Immunology: CVI 12/2014; 22(3). DOI:10.1128/CVI.00720-14 · 2.37 Impact Factor